Compound: milrinone
SMILES: O=c1[nH]c(c(-c2ccncc2)cc1C#N)C
InChIKey: PZRHRDRVRGEVNW-UHFFFAOYSA-N
Synonyms: milrinone, 78415-72-2, Milrila, Milrinona, Milrinonum, Win-47203-2, 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile, 6-methyl-2-oxo-5-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile, JU9YAX04C7, WIN 47203, NSC-760072, DTXSID5023324, WIN 47,203-2, (3,4'-BIPYRIDINE)-5-CARBONITRILE, 1,6-DIHYDRO-2-METHYL-6-OXO-, DTXCID103324, Corotrop, CHEBI:50693, (3,4'-Bipyridine)-5-carbonitrile, 6-dihydro-2-methyl-6-oxo-, [3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo-, Lactate, Milrinone, RefChem:57100, Win47203, C01CE02, 278-903-6, Primacor, Corotrope, 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile, 2-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carbonitrile, MFCD00133539, 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone, 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile, CHEMBL189, 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile, 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile, Milrinonum [Latin], NCGC00015675-08, NCGC00164390-01, Milrinona [Spanish], 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile, CAS-78415-72-2, 2-Methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile (Milrinone), 2-Methyl-6-oxo-1,6-dihydro-[3,4']bipyridinyl-5-carbonitrile, YM 018, SMR000058475, Milrila (TN), WIN 47203-2, CCRIS 3795, SR-01000075524, EINECS 278-903-6, UNII-JU9YAX04C7, BRN 3546821, Milrinone?, Milrinone [USAN:USP:INN:BAN], Milrinone (Primacor), Milrinone (Standard), Tocris-1504, 111GE027, MILRINONE [INN], MILRINONE [JAN], MILRINONE [MI], MILRINONE [USAN], 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)NICOTINONITRILE, Prestwick0_001065, Prestwick1_001065, Prestwick2_001065, Prestwick3_001065, Lopac-M-4659, MILRINONE [VANDF], M1663, MILRINONE [MART.], M 4659, MILRINONE [USP-RS], MILRINONE [WHO-DD], Milrinone (JAN/USP/INN), Lopac0_000737, SCHEMBL36947, BSPBio_001050, MLS000028818, MLS001424052, MLS006011946, BIDD:GT0197, Milrinone - Bio-X trade mark, SPBio_002965, BPBio1_001156, GTPL5225, orb1309788, SCHEMBL8309385, BDBM15296, 2-hydroxy-6-methyl-5-pyridin-4-ylpyridine-3-carbonitrile, 6-methyl-2-oxo-5-(4-pyridyl)-1H-pyridine-3-carbonitrile, MILRINONE [USP MONOGRAPH], GLXC-06520, HMS1571E12, HMS2051L10, HMS2090J14, HMS2098E12, HMS2234A23, HMS3262C16, HMS3267P12, HMS3370H18, HMS3393L10, HMS3656G06, HMS3715E12, HMS3742G09, HMS5081C11, Pharmakon1600-01505489, Tox21_112113, Tox21_400069, Tox21_500737, EBC-08195, HY-14252R, Milrinone, >=97% (TLC), powder, NSC760072, s2484, SBB055743, Milrinone - CAS 78415-72-2, AKOS015836135, Tox21_112113_1, AC-4730, CCG-101020, CCG-204822, CS-1367, DB00235, FM26007, KS-1440, LP00737, NC00270, NSC 760072, SDCCGSBI-0050715.P002, NCGC00015675-01, NCGC00015675-02, NCGC00015675-03, NCGC00015675-04, NCGC00015675-05, NCGC00015675-06, NCGC00015675-07, NCGC00015675-09, NCGC00015675-11, NCGC00015675-24, NCGC00025189-01, NCGC00025189-02, NCGC00025189-03, NCGC00261422-01, BM164671, HY-14252, SMR004703527, SY028050, AB00514027, EU-0100737, NS00007740, SW197308-3, T1096, C07224, D00417, EN300-117244, AB00514027-02, AB00514027-03, AB00514027_04, AB00514027_05, AB00597139-08, F036508, Q847399, SR-01000075524-1, SR-01000075524-3, SR-01000075524-4, SR-01000075524-6, BRD-K67080878-001-05-5, BRD-K67080878-001-15-4, BRD-K67080878-001-16-2, Z1501480412, 6-methyl-2-oxo-5-(4-pyridyl)hydropyridine-3-carbonitrile, 1,2-dihydro-6-methyl-2-oxo-5-(4 -pyridinyl)nicotinonitrile, 2-Methyl-6-oxo-1,6-dihydro[3,4'-bipyridine]-5-carbonitrile, Milrinone, United States Pharmacopeia (USP) Reference Standard, 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)-NICOTINONITRILE, 1,6-Dihydro-2-methyl-6-oxo-(3,4 inverted exclamation mark -bipyridine)-5-carbonitrile
Theoretical properties:
molecular_formula: C12H9N3O
molecular_weight: 211.22 g/mol
exact_mass: 211.074561919 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 1
heavy_atom_count: 16
topological_polar_surface_area: 65.8 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: >300 °C
solubility: <1 mg/mL
Descriptions:
{"pubchem": "Milrinone is a member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. It has a role as a vasodilator agent, a cardiotonic drug, a platelet aggregation inhibitor and an EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor. It is a nitrile, a pyridone and a member of bipyridines.", "chebi": "A member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure.", "chembl": "MILRINONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Milrinone, sold under the brand name Primacor among others, is a pulmonary vasodilator used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.\nOverall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cyclic adenosine monophosphate (cAMP) and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone is used as a drug that causes positive inotropy and it will lead to an increased force of contraction. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival. In critically ill patients with evidence of cardiac dysfunction there is limited good quality evidence to recommend its use.\nMilrinone is administered intravenously and eliminated unchanged in the urine."}